Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

The Lancet Infectious Diseases

Volumn 16, Issue 10, 2016, Pages 1154-1168

  Wheeler, Cosette M ^a   Skinner, S Rachel ^b,c   Del Rosario Raymundo, M Rowena ^d   Garland, Suzanne M ^e,f,g,h   Chatterjee, Archana ⁱ   Lazcano Ponce, Eduardo ^j   Salmerón, Jorge ^k   McNeil, Shelly ^l   Stapleton, Jack T ^m   Bouchard, Céline ⁿ   Martens, Mark G ^o   Money, Deborah M ^p   Quek, Swee Chong ^q   Romanowski, Barbara ^r   Vallejos, Carlos S ^s   ter Harmsel, Bram ^t   Prilepskaya, Vera ^u   Fong, Kah Leng ^v   Kitchener, Henry ^w   Minkina, Galina ^x   Lim, Yong Kuei Timothy ^y   Stoney, Tanya ^b   Chakhtoura, Nahida ^z   Cruickshank, Margaret E ^aa   Savicheva, Alevtina ^ab   da Silva, Daniel Pereira ^ac   Ferguson, Murdo ^l   Molijn, Anco C ^ad   Quint, Wim G V ^ad   Hardt, Karin ^ae   Descamps, Dominique ^ae   Suryakiran, Pemmaraju V ^af   Karkada, Naveen ^af   Geeraerts, Brecht ^ae   Dubin, Gary ^ag   Struyf, Frank ^ae   more..

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d San Pablo Colleges Medical Center   (Philippines)

^e ROYAL WOMEN'S HOSPITAL   (Australia)

^f ROYAL CHILDREN'S HOSPITAL   (Australia)

^g MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^h UNIVERSITY OF MELBOURNE   (Australia)

ⁱ UNIVERSITY OF SOUTH DAKOTA   (United States)

^j INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^k INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^l DALHOUSIE UNIVERSITY   (Canada)

^m UNIVERSITY OF IOWA   (United States)

ⁿ UNIVERSITÉ LAVAL   (Canada)

^o JERSEY SHORE UNIVERSITY MEDICAL CENTER   (United States)

^p UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^q GLENEAGLES HOSPITAL   (Singapore)

^r UNIVERSITY OF ALBERTA   (Canada)

^s National Cancer Institute INEN and Oncosalud   (Peru)

^t Roosevelt Kliniek   (Netherlands)

^u RESEARCH CENTER OF OBSTETRICS   (Russian Federation)

^v SINGAPORE GENERAL HOSPITAL   (Singapore)

^w UNIVERSITY OF MANCHESTER   (United Kingdom)

^x Clinical Oncology Hospital Moscow   (Russian Federation)

^y KK WOMEN'S AND CHILDREN'S HOSPITAL   (Singapore)

^z UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^aa UNIVERSITY OF ABERDEEN   (United Kingdom)

^ab D O OTT RESEARCH INSTITUTE OF OBSTETRICS   (Russian Federation)

^ac Instituto Portugues de Oncologia Francisco Gentil Centro Regional de Oncologia de Coimbra SA   (Portugal)

^ad DDL DIAGNOSTIC LABORATORY   (Netherlands)

^ae GSK   (Belgium)

^af GlaxoSmithKline Pharmaceuticals Ltd   (India)

^ag GLAXOSMITHKLINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; WART VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; VIRUS DNA;

ADULT; ARTICLE; CROSS PROTECTION; CYTOLOGY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOGENICITY; INFECTION PREVENTION; INFECTION RISK; PERSISTENT INFECTION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CARCINOMA IN SITU; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; IMMUNOLOGY; ISOLATION AND PURIFICATION; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

ADJUVANTS, IMMUNOLOGIC; ADULT; DNA, VIRAL; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 84977668330     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(16)30120-7     Document Type: Article

References (36)

1. 1 de Sanjosé, S, Quint, WGV, Alemany, L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 11 (2010), 1048–1056.
2. 2 Bruni, L, Diaz, M, Castellsagué, X, Ferrer, E, Bosch, FX, de Sanjosé, S, Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 202 (2010), 1789–1799.
3. 3 Trottier, H, Ferreira, S, Thomann, P, et al. Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity. Cancer Res 70 (2010), 8569–8577.
4. 4 Romanowski, B, on behalf of The GlaxoSmithKline Vaccine HPV-007 Study Group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6·4 years. Lancet 374 (2009), 1975–1985.
5. 5 Lehtinen, M, Paavonen, J, Wheeler, CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 13 (2012), 89–99.
6. 6 Garland, SM, Hernandez-Avila, M, Wheeler, CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356 (2007), 1928–1943.
7. 7 The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356 (2007), 1915–1927.
8. 8 Muñoz, N, Kjaer, SK, Sigurdsson, K, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 102 (2010), 325–339.
9. 9 Joura, EA, Giuliano, AR, Iversen, OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 372 (2015), 711–723.
10. 10 Skinner, SR, Garland, SM, Stanley, MA, Pitts, M, Quinn, MA, Human papillomavirus vaccination for the prevention of cervical neoplasia: is it appropriate to vaccinate women older than 26?. Med J Aust 188 (2008), 238–242.
11. 11 Black, LL, Zimet, GD, Short, MB, Sturm, L, Rosenthal, SL, Literature review of human papillomavirus vaccine acceptability among women over 26 years. Vaccine 27 (2009), 1668–1673.
12. 12 Bosch, FX, Robles, C, Díaz, M, et al. HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nat Rev Clin Oncol 13 (2016), 119–132.
13. 13 Skinner, SR, Szarewski, A, Romanowski, B, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet 384 (2014), 2213–2227.
14. 14 Muñoz, N, Manalastas, R Jr, Pitisuttithum, P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. Lancet 373 (2009), 1949–1957.
15. 15 Castellsagué, X, Muñoz, N, Pitisuttithum, P, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age. Br J Cancer 105 (2011), 28–37.
16. 16 Paavonen, J, Jenkins, D, Bosch, FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369 (2007), 2161–2170.
17. 17 van Doorn, L-J, Molijn, A, Kleter, B, Quint, W, Colau, B, Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J Clin Microbiol 44 (2006), 3292–3298.
18. 18 van Alewijk, D, Kleter, B, Vent, M, et al. A human papilloma virus testing algorithm comprising a combination of the L1 broad-spectrum SPF10 PCR assay and a novel E6 high-risk multiplex type-specific genotyping PCR assay. J Clin Microbiol 51 (2013), 1171–1178.
19. 19 Dessy, FJ, Giannini, SL, Bougelet, CA, et al. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccine 4 (2008), 425–434.
20. 20 Jennison, C, Turnbull, BW, Group sequential methods with applications to clinical trials. Harrington, D, (eds.), 1999, CRC Press LLC, Florida.
21. 21 O'Brien, PC, Fleming, TR, A multiple testing procedure for clinical trials. Biometrics 35 (1979), 549–556.
22. 22 Herrero, R, Wacholder, S, Rodríguez, A, et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov 1 (2011), 408–419.
23. 23 Szarewski, A, Poppe, WAJ, Skinner, SR, et al. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15–25 years with and without serological evidence of previous exposure to HPV-16/18. Int J Cancer 131 (2012), 106–116.
24. 24 Olsson, S-E, Kjaer, SK, Sigurdsson, K, et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin 5 (2009), 696–704.
25. 25 Rodríguez, AC, Solomon, D, Herrero, R, et al. Impact of human papillomavirus vaccination on cervical cytology screening, colposcopy, and treatment. Am J Epidemiol 178 (2013), 752–760.
26. 26 Hildesheim, A, Wacholder, S, Catteau, G, Struyf, F, Dubin, G, Herrero, R, Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial. Vaccine 32 (2014), 5087–5097.
27. 27 Wheeler, CM, Castellsagué, X, Garland, S, et al. Cross-protective efficacy of the HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 13 (2012), 100–110.
28. 28 Naud, P, Roteli-Martins, CM, De Carvalho, NS, et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9·4 years post-vaccination. Hum Vaccin Immunother 10 (2014), 2147–2162.
29. 29 Kemp, TJ, Hildesheim, A, Safaeian, M, et al. HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine 29 (2011), 2011–2014.
30. 30 Schwarz, T, Spaczynski, M, Kaufman, A, et al. Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15–55 years and first-time modelling of antibody responses in mature women: results from an open-label 6-year follow-up study. BJOG 122 (2015), 107–118.
31. 31 Castle, PE, Wacholder, S, Sherman, ME, et al. Absolute risk of a subsequent abnormal Pap among oncogenic human papillomavirus DNA-positive, cytologically negative women. Cancer 95 (2002), 2145–2151.
32. 32 Brotherton, JML, Fridman, M, May, CL, Chappell, G, Saville, AM, Gertig, DM, Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 377 (2011), 2085–2092.
33. 33 Pagliusi, SR, Aguado, MT, Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 23 (2004), 569–578.
34. 34 Lowy, DR, Herrero, R, Hildesheim, A, Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging. Lancet Oncol 16 (2015), e226–e233.
35. 35 World Health Organization International Agency for Research on Cancer. Primary endpoints for prophylactic HPV vaccine trials. IARC Working Group Report, volume 7. IARC. http://www.iarc.fr/en/publications/pdfs-online/wrk/wrk7/Prophylactic_HPV_VaccineTrials.pdf, 2014 (accessed April 1, 2016).
36. 36 Castle, P, Schmeler, KM, HPV vaccination: for women of all ages?. Lancet 384 (2014), 2178–2180.